Premium
Efficacy of Stronger Neo‐Minophagen C compared between two doses administered three times a week on patients with chronic viral hepatitis
Author(s) -
Miyake Kazuhiko,
Tango Toshiro,
Ota Yasuhiko,
Mitamura Keiji,
Yoshiba Makoto,
Kako Makoto,
Hayashi Shigeki,
Ikeda Yusei,
Hayashida Norimasa,
Iwabuchi Shogo,
Sato Yuzuru,
Tomi Toshiaki,
Funaki Naoya,
Hashimoto Naoaki,
Umeda Tomoyuki,
Miyazaki Jun,
Tanaka Katsuaki,
Endo Yasuo,
Suzuki Hiroshi
Publication year - 2002
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1046/j.1440-1746.2002.02876.x
Subject(s) - glycyrrhizin , medicine , gastroenterology , chronic hepatitis , randomized controlled trial , therapeutic effect , hepatitis , hepatitis a virus , viral hepatitis , surgery , virus , immunology
Background:A daily injection of glycyrrhizin (Stronger Neo‐Minophagen C (SNMC) containing 40 mg glycyrrhizin in a 20 mL ampoule) lowers alanine aminotransferase (ALT) levels in patients with chronic viral hepatitis.Methods:The therapeutic effects of intermittent administration of SNMC three times a week for 12 weeks were evaluated and compared between two doses (40 and 100 mL) in a randomized clinical trial.Results:Overall, the therapeutic response was better in the 53 patients allocated 100 mL than the 59 who were allocated to have 40 mL SNMC ( P = 0.0243). At the completion of SNMC treatment, ALT levels decreased more extensively in the patients on 100 mL than those on 40 mL SNMC (−29 vs −50% in comparison with the baseline value, P = 0.0002). Minor side‐effects occurred in both the patients on 100 mL (20%) and those on 40 mL (12%), but they did not require any therapies.Conclusions:Intermittent SNMC would be efficient in suppressing ALT levels in patients with chronic viral hepatitis in a dose‐dependent manner. Taken along with infrequent and very mild side‐effects, long‐term intermittent SNMC would benefit patients with chronic hepatitis by maintaining their quality of life with easier compliance. © 2002 Blackwell Publishing Asia Pty Ltd